Leonabio Inc (LONA) Stock Price, Quote & News

BioTuesdays Feb. 3 at 4:22 PM

$LONA has appointed Mark F. Kubic as chief business officer (CBO) to lead the company’s business development strategy and execution https://biotuesdays.com/2026/02/03/leonabio-appoints-industry-veteran-mark-f-kubic-as-cbo/

0 · Reply

SebNo1234 Jan. 30 at 3:04 PM

$LONA I hope of good news soon!🍀🤞🚀🍀🤞

0 · Reply

Alyssa_CC Jan. 15 at 7:02 PM

@Pfreakstocks @howardlindzon Thanks for flagging! $LONA has been created and $ATHA messages etc is being transferred over to the new ticker!

0 · Reply

Pfreakstocks Jan. 15 at 4:33 AM

$LONA @howardlindzon this ticker is now $LONA

1 · Reply

Stonky_Mcprofitface Jan. 10 at 5:13 PM

$LONA This name change will help add 500 basis points to their accretive gross margin upside, not to mention blur their shady past.

0 · Reply

Stonky_Mcprofitface Jan. 2 at 3:25 PM

$LONA Spread is pretty wild but it seems to be tamed

0 · Reply

Stonky_Mcprofitface Dec. 30 at 8:42 PM

$LONA This will go back to $4 where it started its improbable, unexplained, preposterous run.

0 · Reply

Ric_1M Dec. 18 at 12:58 PM

$LONA $SOC $DJT $VERU $SPAI "Optimism is a happiness magnet. If you stay positive, good things and good people will be drawn to you." Mary Lou Retton

0 · Reply

Carl_K Jul. 7 at 8:12 PM

$LONA Guy could have made up for his losses being long this week. Looking at all his posts the past days, there wasn't much vacation budget left 😀.

1 · Reply

SalmanAziz Jul. 7 at 7:52 PM

$LONA was a great run.

0 · Reply

LeonaBio Appoints Industry Veteran Mark F. Kubik as Chief Business Officer

Dec 18, 2025, 2:17 PM EST - 6 weeks ago

Why Is Athira Pharma Stock Spiking After Breast Cancer Asset Acquisition?

Dec 18, 2025, 1:47 PM EST - 6 weeks ago

Athira Pharma, Inc. (ATHA) Discusses Acquisition of Rights to Lasofoxifene Phase III Program for Metastatic Breast Cancer Transcript

Dec 18, 2025, 1:09 PM EST - 6 weeks ago

Athira Pharma recovers from Alzheimer's failure with breast cancer pivot and $90M investment

Dec 18, 2025, 7:02 AM EST - 6 weeks ago

Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million

Sep 11, 2025, 9:00 AM EDT - 5 months ago

Athira Pharma Announces Reverse Stock Split

May 13, 2025, 11:00 AM EDT - 9 months ago

Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit

May 9, 2025, 4:05 PM EDT - 9 months ago

Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates

Feb 27, 2025, 4:05 PM EST - 1 year ago

Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates

Jan 7, 2025, 5:15 PM EST - 1 year ago

Seattle biotech firm Athira Pharma will pay $4M to settle allegations related to research misconduct

Dec 6, 2024, 5:30 PM EST - 1 year ago

Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association's 35th International Symposium on ALS/MND

Nov 7, 2024, 4:05 PM EST - 1 year ago

Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates

Sep 17, 2024, 11:59 AM EDT - 1 year ago

Athira Pharma laying off 49 employees, about 70% of workforce, as part of restructuring

Sep 17, 2024, 9:00 AM EDT - 1 year ago

Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases

Sep 4, 2024, 8:48 AM EDT - 1 year ago

Athira Pharma's Alzheimer's Candidate Fails To Improve Cognition And Function In Patients With Mild/Moderate Disease, Stock Sinks

Sep 3, 2024, 4:13 PM EDT - 1 year ago

Athira Pharma's Alzheimer's drug fails in mid-to-late stage trial

Sep 3, 2024, 4:01 PM EDT - 1 year ago

Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer's Disease

Aug 1, 2024, 4:05 PM EDT - 1 year ago

Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates

Jul 31, 2024, 8:05 AM EDT - 1 year ago

Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer's Disease-Related Pathology at the Alzheimer's Association International Conference (AAIC) 2024

Jun 12, 2024, 7:00 AM EDT - 1 year ago

Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer's Disease Patients

May 29, 2024, 7:00 AM EDT - 1 year ago

Athira Pharma to Participate in Upcoming June Conferences

May 17, 2024, 5:00 PM EDT - 1 year ago

Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action

May 15, 2024, 4:05 PM EDT - 1 year ago

Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates

May 2, 2024, 7:00 AM EDT - 1 year ago

Athira Pharma to Participate in Upcoming May Conferences

Apr 15, 2024, 7:00 AM EDT - 1 year ago

Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer

Apr 11, 2024, 7:00 AM EDT - 1 year ago

Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer's Disease

Apr 3, 2024, 7:00 AM EDT - 1 year ago

Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting

Mar 8, 2024, 7:00 AM EST - 2 years ago

Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer's and Parkinson's Diseases at AD/PD™ 2024 International Conference

Feb 22, 2024, 4:05 PM EST - 2 years ago

Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates

Feb 8, 2024, 4:02 PM EST - 2 years ago

Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)

Jan 8, 2024, 7:00 AM EST - 2 years ago

Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update

Jan 3, 2024, 7:00 AM EST - 2 years ago

Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer's Disease

Dec 12, 2023, 7:00 AM EST - 2 years ago

Athira Pharma Announces Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies

Nov 29, 2023, 7:00 AM EST - 2 years ago

Athira Pharma to Participate in Sidoti December Small Cap Investor Conference

Nov 15, 2023, 8:15 AM EST - 2 years ago

Athira Pharma Presents Preclinical Data Highlighting Fosgonimeton's Neuroprotective Effects Against Amyloid-β-Induced Pathological Alterations and Neuroinflammation in Models of Alzheimer's Disease

Nov 8, 2023, 7:00 AM EST - 2 years ago

Athira Pharma to Participate in Jefferies London Healthcare Conference

Oct 5, 2023, 4:30 PM EDT - 2 years ago

Athira Pharma Presents Preclinical Data Further Supporting the Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)

Sep 19, 2023, 7:00 AM EDT - 2 years ago

Athira Pharma to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference

Aug 10, 2023, 4:05 PM EDT - 2 years ago

Athira Pharma Reports Second Quarter 2023 Financial Results and Pipeline and Business Updates

Jul 17, 2023, 7:00 AM EDT - 2 years ago

Athira Pharma Presents Phase 2 Clinical Data Correlating Improvements in Biomarkers of Neurodegeneration and Neuroinflammation with Improvements in Measures of Cognition and Function in Alzheimer's Disease

Jul 6, 2023, 7:00 AM EDT - 2 years ago

Athira Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2023

May 22, 2023, 7:00 AM EDT - 2 years ago

Athira Pharma Appoints Andrew Gengos as Chief Financial Officer and Chief Business Officer

May 8, 2023, 7:00 AM EDT - 2 years ago

Athira Pharma to Participate in Upcoming May Investor Conferences

Apr 25, 2023, 4:01 PM EDT - 3 years ago

Athira Pharma Presents New Clinical and Preclinical Data at the American Academy of Neurology (AAN) 2023 Annual Meeting

Apr 11, 2023, 7:00 AM EDT - 3 years ago

Athira Pharma Announces Upcoming Presentations at the American Academy of Neurology (AAN) 2023 Annual Meeting

Mar 28, 2023, 1:00 AM EDT - 3 years ago

Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of Fosgonimeton for Alzheimer's and Parkinson's Diseases at AD/PD™ 2023 International Conference

Mar 23, 2023, 4:05 PM EDT - 3 years ago

Athira Pharma Reports Full Year 2022 Financial Results and Recent Pipeline and Business Updates

Mar 6, 2023, 7:00 AM EST - 3 years ago

Athira Pharma to Present Data Supporting Therapeutic Potential of Enhancing HGF/MET Neurotrophic System at Upcoming Scientific Conferences

Feb 1, 2023, 7:00 AM EST - 3 years ago

Athira Pharma Announces Publication in Journal of Alzheimer's Disease Highlighting Need for Novel Alzheimer's Disease Treatment Approaches and Potential of Enhancing HGF/MET Pathway

Jan 31, 2023, 7:00 AM EST - 3 years ago

Athira Pharma Announces Promotion of Kevin Church, Ph.D., to Chief Scientific Officer

BioTuesdays Feb. 3 at 4:22 PM

0 · Reply

SebNo1234 Jan. 30 at 3:04 PM

$LONA I hope of good news soon!🍀🤞🚀🍀🤞

0 · Reply

Alyssa_CC Jan. 15 at 7:02 PM

@Pfreakstocks @howardlindzon Thanks for flagging! $LONA has been created and $ATHA messages etc is being transferred over to the new ticker!

0 · Reply

Pfreakstocks Jan. 15 at 4:33 AM

$LONA @howardlindzon this ticker is now $LONA

1 · Reply

Stonky_Mcprofitface Jan. 10 at 5:13 PM

$LONA This name change will help add 500 basis points to their accretive gross margin upside, not to mention blur their shady past.

0 · Reply

Stonky_Mcprofitface Jan. 2 at 3:25 PM

$LONA Spread is pretty wild but it seems to be tamed

0 · Reply

Stonky_Mcprofitface Dec. 30 at 8:42 PM

$LONA This will go back to $4 where it started its improbable, unexplained, preposterous run.

0 · Reply

Ric_1M Dec. 18 at 12:58 PM

$LONA $SOC $DJT $VERU $SPAI "Optimism is a happiness magnet. If you stay positive, good things and good people will be drawn to you." Mary Lou Retton

0 · Reply

Carl_K Jul. 7 at 8:12 PM

$LONA Guy could have made up for his losses being long this week. Looking at all his posts the past days, there wasn't much vacation budget left 😀.

1 · Reply

SalmanAziz Jul. 7 at 7:52 PM

$LONA was a great run.

0 · Reply

Mitch___Picks Jul. 7 at 7:50 PM

Swing ideas into tomorrow: $LONA $KERN $DBGI $FWBI $EJH

0 · Reply

SalmanAziz Jul. 7 at 7:42 PM

$LONA this was a nice run. Keep cashing out the winners. Just added more to $BKSY to my portfolio. This is displaying a beautiful flag pattern, just a matter of time before the next leg up.

1 · Reply

Mitch___Picks Jul. 7 at 5:43 PM

$LONA $KERN I don’t need to post these swings everyday. Been pretty low risk from original entries. ATHA 5+, KERN .20+ minimum. This is what trading is all about.

0 · Reply

kubota2323 Jul. 7 at 5:09 PM

$LONA $ADPT $FDMT adding on any weakness. Giddy up.

0 · Reply

viking1111 Jul. 7 at 3:34 PM

$LONA lol shorting the bottom not a good idea.

0 · Reply

TraderHabbit Jul. 7 at 3:34 PM

$LONA yeah right ! Where is he? Seriously 😒

0 · Reply

TraderHabbit Jul. 7 at 3:30 PM

$LONA he told me it doesn’t make sense? 🤡

0 · Reply

TheSleeeve Jul. 7 at 3:27 PM

$LONA See? Congrats longs!

0 · Reply

debbiekatz Jul. 7 at 3:22 PM

Two stocks i told my team "will double" recently $ATHA 3.81 now - posted for them at 2.79 (up 37% so far) $ADTH 3.21 now - posted here at 2.5 (up 28% so far)

1 · Reply

Nmcbride Jul. 7 at 3:05 PM

$LONA I was thinking I'd sell a bunch high and rebuy low like yesterday. Today there's been no dip. Target of 6, does that mean we'll see a lot of daily fluctuation next week? I'm asking for opinions, I don't know what will happen. I personally am looking for a 10$ target.

1 · Reply

OnlyTitz Jul. 7 at 2:11 PM

@Marketplay @NoTemplarOK still holfing $LONA from @HotStuff 's revommendation

1 · Reply

Market Cap	18.69M
Revenue (ttm)	0.00
Net Income (ttm)	-96.94M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	22,900
Avg Vol	1,307,984
Day's Range	N/A - N/A
Shares Out	3.94M
Stochastic %K	12%
Beta	2.79
Analysts	Hold
Price Target	$4.00